Focus: Parexel is a large Contract Research Organization (CRO) headquartered in Boston with 10,001–50,000 employees, providing clinical development, regulatory, and operations services across the pharmaceutical development lifecycle. As a major CRO, it executes trials and regulatory strategies for global pharma and biotech clients.
Profile data last refreshed 15h ago · AI intelligence enriched 1mo ago
Hot — 374 jobs added in 30d
Net +148 (374 new, 226 removed). Aggressive expansion phase.
Parexel is an excellent destination for clinical operations, regulatory affairs, and project management professionals seeking large-scale trial portfolio exposure and geographic expansion opportunities, but private status and limited visa sponsorship warrant due diligence on stability and relocation policies.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Parexel
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Parexel's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Parexel sees biotech funding recovery fuel growth; India emerges as key GCC and pharma market - Moneycontrol.com
Parexel sees biotech funding recovery fuel growth; India emerges as key GCC and pharma market Moneycontrol.com
8-K Filing: Azenta, Inc. (AZTA) (CIK 0000933974) — 8-K
8-K
8-K Filing: Vistagen Therapeutics, Inc. (VTGN) (CIK 0001411685) — EX-99.1
EX-99.1
8-K Filing: Replimune Group, Inc. (REPL) (CIK 0001737953) — EXHIBIT 99.1
EXHIBIT 99.1
Parexel recognised among world's top disability inclusive businesses - Indian Pharma Post
Parexel recognised among world's top disability inclusive businesses Indian Pharma Post
8-K Filing: WINDTREE THERAPEUTICS INC /DE/ (WINT) (CIK 0000946486) — EXHIBIT 99.1
EXHIBIT 99.1
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies.
Assessing the consistency of overall survival extrapolations in Swedish health technology assessment reports of oncology treatments using extended follow-up data.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo